These 4 Biotech Penny Stocks Are Buys, According to Analysts
Four biotech penny stocks with upside to analyst price targets ranging from 42% to 291%.
Biotech Stocks
This Recent Biotech IPO Has The Right Story At The Right Time – And The Right Pattern
The author of today’s article notes that high-profile IPOs typically follow a pattern – and given this pattern, he is bullish on “a biotech stock that went public just under a month ago with a story that perfectly fits the times, and whose stock has followed exactly that pattern.”
Why Individual Stock Selection Will Be Key For Biotech Investors In 2021 – And RBC’s 15 Top Ideas
When it comes to biotech investing in 2021, healthcare stock analysts at RBC advised in a recent report that “Many pandemic-related influences are setting up the sector for outperformance but several factors could still work against the group, making individual stock selection a key priority…”
Promising Test Results For Its Cancer Drugs Just Launched This Small Biotech To A Record High
On Monday, the small biotech stock highlighted in today’s article hit a record high, skyrocketing 95.1%. The catalyst?
The Hype And The Data Behind This Breast Cancer Stock’s Massive Surge
The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.
These Biotechs Are Awaiting FDA Rulings In December
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
This Under-The-Radar Biotech’s Unique Approach To Drug Development Could Supercharge Your Portfolio
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.
2 Recommendations For Biotech Upside
Hated stocks and biotech are the best bets right now.
“Explosive Growth Potential”: 2 Under-The-Radar Cancer Drugmakers For Risk-Tolerant Investors
Which developmental-stage biotechs have the potential to beat the difficult odds and successfully get their novel drugs to market?
These 2 Coronavirus Vaccine Stocks Offer “The Best Of Both Worlds”
Of the two “best of both worlds” biotech stocks highlighted in today’s article – “companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years”.